Back

Piramal Pharma to Buy the Remaining 26% Stake in Yapan Bio

Piramal Pharma has decided to exercise its call option for the balance 26% of vaccines and biologics CDMO Yapan Bio, lifting its holding from 74% to 100%.

Piramal Pharma Yapan Bio deal: Piramal Pharma Limited logo over scientists talking in a laboratory

Key Takeaways

  • Piramal Pharma will buy the remaining 26% equity stake in Yapan Bio by exercising its call option.
  • Its holding is set to rise from 74% to 100%, making Yapan Bio a wholly owned subsidiary.
  • The acquisition price and the share transfer date have not been finalised yet.
  • Yapan Bio is a Hyderabad-based CDMO for vaccines and biologics.
  • Piramal Pharma first invested in Yapan Bio in December 2021 and raised its stake to 74% in August 2026.
Table of Contents 6 sections
  1. Piramal Pharma's Yapan Bio buyout at a glance
  2. How Piramal Pharma's board cleared the Yapan Bio call option
  3. Yapan Bio, the Hyderabad vaccines and biologics CDMO
  4. What Piramal Pharma has said about closing the Yapan Bio deal
  5. Where Piramal Pharma's Yapan Bio stake stands now
  6. FAQs

Piramal Pharma will acquire the remaining 26% equity stake in Yapan Bio Private Limited, a contract development and manufacturing organisation (CDMO) for vaccines and biologics. The drugmaker told the stock exchanges on November 18, 2026 that it has decided to exercise its call option for the balance stake.

Piramal Pharma already owns 74% of Yapan Bio. Once the deal is completed, its holding is set to rise to 100%, and Yapan Bio will become a wholly owned subsidiary. The price for the stake and the date on which the shares will change hands have not been finalised yet.

Piramal Pharma's Yapan Bio buyout at a glance

DetailValue
BuyerPiramal Pharma Limited
TargetYapan Bio Private Limited
Stake being boughtRemaining 26%
RouteExercise of Piramal Pharma's call option
Approved byAdministrative committee authorised by Piramal Pharma's board
Holding now74%
Holding after completion100% (wholly owned subsidiary)
Price and transfer dateNot finalised yet
AnnouncedNovember 18, 2026

How Piramal Pharma's board cleared the Yapan Bio call option

The decision was approved by an administrative committee of Piramal Pharma's board of directors, acting under powers given to it by the board. Piramal Pharma said that after exercising the call option, it is in talks with Yapan Bio's shareholders on the matters needed to complete the deal.

The exercise of the option does not mean the shares have already moved. The final terms, including the acquisition price and the effective date of the share transfer, are still to be settled.

Yapan Bio, the Hyderabad vaccines and biologics CDMO

Yapan Bio is a Hyderabad-based CDMO. It offers process development, characterisation and Phase I/II GMP manufacturing services for vaccines and biologics.

Piramal Pharma first bought a 27.78% stake in December 2021 for Rs 101.77 crore. In August 2026, it bought an additional 40.67% stake for about Rs 76 crore, taking its holding from 33.33% to 74%, and Yapan Bio changed from an associate company into a subsidiary. Yapan Bio works within Piramal Pharma Solutions, Piramal Pharma's CDMO business.

WhenWhat happened
December 2021Piramal Pharma invested Rs 101.77 crore in Yapan Bio for a 27.78% stake
August 2026Piramal Pharma bought an additional 40.67% stake for about Rs 76 crore, raising its holding from 33.33% to 74% and making Yapan Bio a subsidiary
November 18, 2026Piramal Pharma decided to exercise its call option for the remaining 26% stake

What Piramal Pharma has said about closing the Yapan Bio deal

Piramal Pharma said it will make further disclosures once the definitive documents are signed and the transaction is completed.

Where Piramal Pharma's Yapan Bio stake stands now

Piramal Pharma holds 74% of Yapan Bio today, after starting with a 27.78% stake in December 2021. The purchase of the remaining 26% would make Yapan Bio a wholly owned subsidiary. Piramal Pharma said it is in talks with Yapan Bio's shareholders to complete the deal.

More news

Join Us Add as preferred source
Share

Frequently Asked Questions

What is Yapan Bio?

Yapan Bio Private Limited is a Hyderabad-based contract development and manufacturing organisation that offers process development, characterisation and Phase I/II GMP manufacturing services for vaccines and biologics.

How much of Yapan Bio is Piramal Pharma buying?

Piramal Pharma is buying the remaining 26% equity stake in Yapan Bio.

How much of Yapan Bio does Piramal Pharma own now?

Piramal Pharma currently owns 74% of Yapan Bio.

How will Yapan Bio's status change after the deal?

Once the deal is completed, Piramal Pharma's holding in Yapan Bio is set to rise to 100% and Yapan Bio will become a wholly owned subsidiary of Piramal Pharma.

How is Piramal Pharma acquiring the Yapan Bio stake?

Piramal Pharma is acquiring the remaining Yapan Bio stake by exercising its call option for the balance 26%.

Who approved Piramal Pharma's Yapan Bio deal?

An administrative committee authorised by Piramal Pharma's board of directors approved the exercise of the call option for the Yapan Bio stake.

What price is Piramal Pharma paying for the Yapan Bio stake?

Piramal Pharma has not finalised the price for the remaining 26% stake in Yapan Bio yet.

When will the Yapan Bio shares be transferred to Piramal Pharma?

The effective date for the transfer of the Yapan Bio shares has not been finalised yet.

When did Piramal Pharma announce the Yapan Bio deal?

Piramal Pharma informed the stock exchanges about the Yapan Bio call option on November 18, 2026.

When did Piramal Pharma first invest in Yapan Bio?

Piramal Pharma first invested in Yapan Bio in December 2021, putting in Rs 101.77 crore for a 27.78% stake.

How did Piramal Pharma reach a 74% stake in Yapan Bio?

In August 2026, Piramal Pharma bought an additional 40.67% of Yapan Bio for about Rs 76 crore, which raised its holding from 33.33% to 74%.

What has Piramal Pharma said about the next step in the Yapan Bio deal?

Piramal Pharma said it is in talks with Yapan Bio's shareholders and will make further disclosures once the definitive documents are signed and the deal is completed.

More in Business